Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

NCT04356742 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

198

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Dapagliflozin 10mg
DRUG: Placebo
DRUG: Evogliptin 5mg
DRUG: Metformin≥1000mg

Sponsor

Dong-A ST Co., Ltd.